OTCMKTS:ATBPF Antibe Therapeutics (ATBPF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 11/2/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Antibe Therapeutics Stock (OTCMKTS:ATBPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Antibe Therapeutics alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.11▼$0.89VolumeN/AAverage Volume27,352 shsMarket Capitalization$11.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Antibe Therapeutics Inc. is a Canadian biotechnology company that has focused on developing therapies for pain and inflammation. Its research centers on hydrogen sulfide-releasing medicines designed to preserve the pain-relieving and anti-inflammatory benefits of nonsteroidal anti-inflammatory drugs while potentially reducing gastrointestinal damage and other safety concerns associated with conventional NSAIDs. The company’s lead investigational product has been ATB-346, an orally administered, hydrogen sulfide-releasing derivative of naproxen. Antibe has evaluated the compound as a potential treatment for conditions involving acute and chronic pain, including osteoarthritis. The product remains investigational and is not an approved commercial medicine. Based in Canada, Antibe has historically advanced its programs through preclinical research and clinical development activities. Publicly available information about the company’s current operations, leadership and commercial presence is limited, and its development status may have changed following funding and clinical-development challenges.AI Generated. May Contain Errors. Read More Receive ATBPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATBPF Stock News HeadlinesAPLIF Appili Therapeutics Inc.August 23, 2024 | seekingalpha.comANTIBE THERAPEUTICS INC (ATBPF) stock forecast and price targetJuly 19, 2024 | finance.yahoo.comxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again until age 85. In 2008, one bad year wiped out more than half the savings of those aged 56 to 65. Today, the national debt stands at 38.86 trillion dollars, far higher than in 1929. See where your retirement stands with a free Retirement Protection Kit.November 3 at 1:00 AM | USA Capital Gold (Ad)Antibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | finance.yahoo.comAntibe Therapeutics reports Q2 resultsNovember 13, 2023 | msn.comAntibe Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationNovember 9, 2023 | finance.yahoo.comIs Antibe Therapeutics (TSE:ATE) In A Good Position To Deliver On Growth Plans?October 20, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul’s New FormulationOctober 18, 2023 | finance.yahoo.comSee More Headlines ATBPF Stock Analysis - Frequently Asked Questions How have ATBPF shares performed this year? Antibe Therapeutics' stock was trading at $0.2156 on January 1st, 2026. Since then, ATBPF stock has increased by 0.0% and is now trading at $0.2156. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (OTCMKTS:ATBPF) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. How do I buy shares of Antibe Therapeutics? Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Antibe Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antibe Therapeutics investors own include Aurora Cannabis (ACB), GoHealth (GOCO), Immunic (IMUX), 9 Meters Biopharma (NMTR), Alibaba Group (BABA), Rithm Capital (RITM) and Block (XYZ). Company Calendar Last Earnings11/13/2023Today11/03/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ATBPF CIKN/A Webwww.antibethera.com Phone(416) 922-3460FaxN/AEmployees11Year Founded2009Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.48% Return on Assets-29.07% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.37Miscellaneous Outstanding Shares52,981,000Free Float48,238,000Market Cap$11.42 million OptionableNot Optionable Beta0.51 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:ATBPF) was last updated on 11/2/2026 by MarketBeat.com Staff. From Our PartnersxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again un...USA Capital Gold | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATBPF Stock Alerts